Literature DB >> 19388160

Inhibiting complement activation on cells at the step of C3 cleavage.

M Kathryn Liszewski1, Celia J Fang, John P Atkinson.   

Abstract

Nearly half of the proteins in the complement system serve in regulation. Control at the central step of C3 activation is provided by an orchestrated interplay of membrane and plasma regulators. A model system employing Chinese hamster ovary (CHO) cells transfected with human regulators was employed to assist in making functional comparisons. Also, in this experimental setup, the pathway and magnitude of complement activation can be varied while monitoring C4b/C3b deposition and cleavage as well as cytotoxicity. This review describes lessons learned and the application of this model for functionally characterizing mutations in regulators associated with atypical hemolytic uremic syndrome.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19388160      PMCID： PMC2768381          DOI： 10.1016/j.vaccine.2008.11.001

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Complement. Second of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

2.  Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.

Authors:  W G Brodbeck; C Mold; J P Atkinson; M E Medof
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

3.  Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

Authors:  Fadi Fakhouri; Mathieu Jablonski; Jacques Lepercq; Jacques Blouin; Alexandra Benachi; Maryvonne Hourmant; Yves Pirson; Antoine Dürrbach; Jean-Pierre Grünfeld; Bertrand Knebelmann; Véronique Frémeaux-Bacchi
Journal:  Blood       Date:  2008-07-24       Impact factor: 22.113

4.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

5.  Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis.

Authors:  A Kojima; K Iwata; T Seya; M Matsumoto; H Ariga; J P Atkinson; S Nagasawa
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

6.  Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Authors:  Maria L Barilla-LaBarca; M Kathryn Liszewski; John D Lambris; Dennis Hourcade; John P Atkinson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

7.  Functional properties of membrane cofactor protein of complement.

Authors:  T Seya; J P Atkinson
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

8.  Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).

Authors:  T Seya; M Okada; M Matsumoto; K S Hong; T Kinoshita; J P Atkinson
Journal:  Mol Immunol       Date:  1991-10       Impact factor: 4.407

9.  Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism.

Authors:  T J Oglesby; C J Allen; M K Liszewski; D J White; J P Atkinson
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307
View more
  15 in total

1.  A quantitative lateral flow assay to detect complement activation in blood.

Authors:  Elizabeth C Schramm; Nick R Staten; Zhouning Zhang; Samuel S Bruce; Christopher Kellner; John P Atkinson; Vasileios C Kyttaris; George C Tsokos; Michelle Petri; E Sander Connolly; Paul K Olson
Journal:  Anal Biochem       Date:  2015-02-04       Impact factor: 3.365

2.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 3.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

Review 4.  CD46 in innate and adaptive immunity: an update.

Authors:  J Cardone; G Le Friec; C Kemper
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

Review 5.  Protective autoantibodies in the rheumatic diseases: lessons for therapy.

Authors:  Gregg J Silverman; Jaya Vas; Caroline Grönwall
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

Review 6.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

7.  Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus.

Authors:  Julia A Sharp; Kenji M Cunnion
Journal:  Mol Immunol       Date:  2010-12-15       Impact factor: 4.407

8.  Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Authors:  John B Johnson; Douglas S Lyles; Martha A Alexander-Miller; Griffith D Parks
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

9.  Antagonism of the complement component C4 by flavivirus nonstructural protein NS1.

Authors:  Panisadee Avirutnan; Anja Fuchs; Richard E Hauhart; Pawit Somnuke; Soonjeon Youn; Michael S Diamond; John P Atkinson
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

10.  Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Authors:  Yujia Li; John B Johnson; Griffith D Parks
Journal:  Virology       Date:  2016-08-06       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.